Human immunodeficiency virus (HIV) in children
- Claudia A. Chiriboga MD, MPH
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Recent advances in antiretroviral treatment have changed the landscape of pediatric HIV—not only has perinatal treatment markedly diminished HIV transmission rates, but highly active antiretroviral treatments (HAART) have, with few exceptions, transformed HIV into a chronic nonfatal disorder. Antiretroviral therapies are complex and fraught with potential for side effects. The neurologist involved with HIV-infected children should have a firm grasp on the different therapeutic agents used among infected children, especially as regards drug metabolism and indications for treatment.
- Gelbard HA, Epstein LG: HIV-1 encephalopathy in children. Curr Opin Pediatr 1995, 7:655–662.
- Belman AL: AIDS and pediatric neurology. Neurol Clin 1990, 8:571–603.
- 1994 Revised classification system for human immunodefiociency virus (HIV) infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1995, 8:30-44. Although from 1995, this is a landmark article describing changes in classification of HIV-infected children (clinical and immunologic).
- Enting RH, Hoetelmans RM, Lange JM, et al.: Antiretroviral drugs and the central nervous system. AIDS 1998, 12:1941–1955. Useful article for neurologists, because it focuses on CNS penetration of antiretroviral agents. CrossRef
- Reddington C, Cohen J, Baldillo A, et al.: Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000, 19:1148–1153. CrossRef
- Working Group on Antiretroviral Therapy and Medical Management of Infants, Children and Adolescents with HIV infection: Antiretroviral therapy and medical management of pediatric HIV infection. Pediatrics 1998, 102:1005–1062.
- Working Group on Antiretroviral Therapy and Medical Management of Infants, Children and Adolescents with HIV infection: Guidelines for the use of antiretroviral agents in Pediatric HIV infection. HIV/AIDS Treatment Information Center/US Department of Health and Human Services. Available at: http://www.hivartis. org/Pediatrics/Aug01_01. Authoritative and comprehensive article on HIV treatment in children. A “must read” for neurologists who treat HIVinfected children.
- Center for Disease Control and Prevention: Guideline for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998, 47:43–82. Important article providing HIV treatment guidelines for adolescents.
- Brambilla D, Reichelderfer PS, Bremer JW, et al.: The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. AIDS 1999, 13:2269–2279. CrossRef
- Hughes MD, Johnson VA, Hirsch MS, et al.: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997, 126:929–938.
- Shearer WT, Quinn TC, LaRussa P, et al.: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997, 336:1337–1342. CrossRef
- Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998, 47:1-30.
- Connor EM, Sperling L, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1995, 331:1173–1180. CrossRef
- GortmakerS, Hughes M, Cervia J, et al.: Effects of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV. N Engl J Med 2001, 345:1522–1588. First large prospective US study to confirm decreased morbidity and mortality with highly active antiretroviral therapy (HAART) in children. CrossRef
- Chadwick EG, Palumbo LA, Rodman J, et al.: Early therapy with Ritonavir (RTV), ZDV and 3TC in HIV infected children 1–24 months. Abstract presented at the Eighth Annual Conference on Antiretroviral and Opportunistic Infections; February 4, 2001; Chicago, IL.
- Wiznia A, Stanley K, Krogstad P, et al.: Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 2000, 16:1113–1121. CrossRef
- De Martino M, Tovo PA, Balducci M, et al.: Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000, 284:190–197. CrossRef
- Laufer DS, Starr SE: Resistance to antivirals. Pediatr Clin North Am 1995, 42:583–599.
- Dalakas MC: Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001, 6:14–20. Excellent review article on the topic of HIV and antiretroviral drugs on the peripheral nervous system. CrossRef
- Kelleher T, Cross A, Dunkle L: Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clin Ther 1999, 21:1182–1192. CrossRef
- Fung HB, Kirschenbaum HL, Hameed R: Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther 2000, 22:549–572. CrossRef
- Hervey PS, Perry CM: Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 2000, 60:447–479. CrossRef
- Horneff G, Adams O, Wahn V: Preliminary experiences with ritonavir in children with advanced HIV infection. Infection 1999, 27:103–107. CrossRef
- Eagling VA, Back DJ, Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997, 44:190–194. CrossRef
- Tsiodras S, Mantzoros C, Hammer S, Samore M: Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000, 160:2050–2056. CrossRef
- Arpadi SM, Cuff PA, Horlick M, et al.: Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001, 24:30–34. Interesting article describing factors associated with lypodystrophy syndrome in HIV-infected children.
- Nachman SA, Stanley K, Yogev R, et al.: Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000, 283:492–498. CrossRef
- Luzuriaga K, McManus M, Catalina M, et al.: Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000, 74:6984–6991. CrossRef
- Starr SE, Fletcher CV, Spector SA, et al.: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999, 341:1874–1881. CrossRef
- Human immunodeficiency virus (HIV) in children
Current Treatment Options in Neurology
Volume 4, Issue 3 , pp 213-224
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Department of Neurology, Division of Pediatric Neurology, College of Physicians and Surgeons, Columbia University, 710 West 168th Street, 10032, New York, NY, USA